Syngene International

Quick check

The five things to look at first. Open one for more.

• DebtHigh safetyRated AA+ by ICRA.
• ResultsLoss-makingLost ₹9 Cr in the Jun 2026 quarter, after a profit a year earlier.
• DilutionNo new sharesNo new shares issued in the last year, so existing shareholders' slices were not cut.
• PromotersSteadyThe promoters (founders or parent) own 53% of the company, about the same as in Jun 2025.
• ValuationCheap vs its pastThe share trades at 50 times its yearly earnings (P/E), cheaper than 89% of the time in the last 5 years. Its usual P/E is about 55.

Syngene International against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.

• Valuation (P/E)50 against a typical 34.2: pricier than most peers (1st = cheapest).9th of 11
• Sales growth−15.8% against a typical +16.4% from a year earlier.8th of 10
• Profit growth−110.4% against a typical 0% from a year earlier.5th of 5
• Share price, 3 months−11% against a typical −13%.5th of 11
• Size₹ 14,839.3 Cr. market value against a typical ₹ 197.8 Cr. (1st = largest).1st of 11

Exchange filings and their impact on the company.

• 27 Oct 2026Change in ManagementMedium impactNegativePrice +9.9% so far today
  CFO to exit and strategy head resigns amid weak results, raising near-term leadership uncertainty.

  Syngene said CFO Deepak Jain has decided to move on for personal reasons and will stay for a mutually agreed transition, while Head of Strategy Ajay Tandon resigns effective October 30, 2026. Two other executive committee members, Head of Chemistry Subhendu Kumar and Head of Biology Priyaranjan Pattanaik, were moved from SMP to non-SMP effective October 27, 2026. The finance and strategy exits during a weak earnings phase add near-term leadership uncertainty despite the planned handover.

  Full analysisFiling
• 27 Oct 2026Outcome of Board MeetingHigh impactNegativePrice +9.9% so far today
  Weak Q2/H1 with revenue down 12% and profit down 85% signals a ~10% revenue and ~40% profit cut for the next 12 months.

  Syngene reported Q2 FY27 consolidated revenue of Rs 832.7 crore, down 8.5% from last year but up from Q1, with net profit of Rs 32.2 crore down 52% year-on-year. For the first half, revenue was Rs 1,568.7 crore down 12% and profit was Rs 23.2 crore down 85%, hit by Rs 111.5 crore forex losses and Rs 20.2 crore exceptional staff costs. Operating cash flow was negative and cash fell while short-term borrowings rose, though the US biologics site build-up continued with Rs 487.6 crore in capital work-in-progress.

  Full analysisFiling

Results dates and other board meetings. Full calendar

Compounded yearly rates over each period.

Listed companies in the same business.

Kiran Mazumdar Shaw

Executive Chairman of the Board

Siddharth Mittal

Chief Executive Officer, Managing Director, Additional Director

Deepak Jain

Chief Financial Officer

Maninder Kapoor Puri

Chief Human Resources Officer

Alex Del Priore

Senior Vice President - Manufacturing Services

Gaurav Kushwaha

Chief Technology Officer

Jayashree Aiyar

Chief Scientific Officer

Chethan Yogesh

Compliance Officer, Company Secretary